Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

The BIOSECURE Act should provide for additional financial, legal, and diplomatic assistance ... AbbVie employee who may have disclosed confidential information to support BeiGene's own drug programs.

It is the cost of the medication, whether or not a patient assistance program is going to have enough ... reported affiliations with AbbVie, Inc; AnHeart Therapeutics; Apollomics, Inc; AstraZeneca ...

ERYTHRO is an ongoing multi-country, multi-site retrospective medical chart review study of adult patients with moderate to severe SLE who participated in the early access program (EAP ... Writing ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

and ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age ...

Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...

For the third year in a row, the hundreds of millions of dollars poured into commercials for AbbVie’s immunology ... Their top individual TV programs, meanwhile, were split between two targets ...